The Experts below are selected from a list of 171 Experts worldwide ranked by ideXlab platform
Ståhle Mona - One of the best experts on this subject based on the ideXlab platform.
-
HLA-B*27 is significantly enriched in Nordic patients with psoriatic Arthritis Mutilans.
Clinical And Experimental Rheumatology S.A.S, 2021Co-Authors: Nikamo Pernilla, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Padyukov Leonid, Ståhle MonaAbstract:To access publisher's full text version of this article click on the hyperlink belowObjectives: The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic Arthritis Mutilans (PAM), a severe and rare form of psoriatic Arthritis (PsA). Methods: Cohorts of patients with the diagnosis of psoriasis vulgaris with or without Arthritis (n=1217), psoriasis without Arthritis (n=534), psoriatic Arthritis without mutilating disease (n=337) and psoriatic Arthritis Mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes. Results: The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset. Conclusions: HLA-B*27 emerges as an important genotype marker for PAM.UK Research & Innovation (UKRI) Medical Research Council UK (MRC) European Commission Swedish Psoriasis Association Finsen Foundation Karolinska Institutet Nordic Psoriasis Patient Society (NORDPSO
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.Peer reviewe
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study.
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadObjective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged ≥18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.NORDPS
-
Radiographic scoring systems for psoriatic Arthritis are insufficient for psoriatic Arthritis Mutilans: results from the Nordic PAM Study.
'SAGE Publications', 2020Co-Authors: Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Ståhle Mona, Jonmundsson Thorarinn, Gudbjornsson BjornAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadBackground: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis (PsA). Purpose: To describe the radiological features in PAM and explore whether existing scoring systems for radiological damage in psoriatic Arthritis are applicable for PAM. Material and methods: Radiographs were scored according to the modified Sharp-van der Heijde (mSvdH) and the Psoriatic Arthritis Ratingen Score (PARS) systems for PsA. Results: At inclusion, 55 PAM patients (49% women, mean age 58 ± 12 years) had conventional radiographs of both hands and feet. A total of 869 PAM joints were detected and 193 joints with ankylosis. The mean total mSvdH score was 213.7 ± 137.8 (41% of maximum) with a higher score for hands than for feet: 136.6 ± 90.1 vs. 79.1 ± 60.9. However, the total score was relatively higher in the feet than in the hands when compared to the highest possible scoring (47% vs. 38% of max). The mean total PARS score was 126.3 ± 79.6 (35% of max). Scoring for joint destruction was higher than for proliferation (22% vs. 11% of max). Strong correlation was found between mSvdH and PARS (r2 = 0.913). A significant correlation was found between scoring and duration of Arthritis and the Health Assessment Questionnaire. History of smoking, BMI, and gender did not influence the scoring values. Conclusions: The two scoring systems studied may not be ideal to indicate progression of PAM in advanced disease since they reach ceiling effects rather early. Therefore, reporting early signs suggestive of PAM, e.g. signs of pencil-in-cup deformities or osteolysis, is crucial. This would reveal the presence of PAM and might lead to improved treatment in order to minimize joint damage. Keywords: Psoriatic Arthritis; Mutilans; psoriasis; radiology; scoring systems.NORDPS
Gudbjornsson Bjorn - One of the best experts on this subject based on the ideXlab platform.
-
HLA-B*27 is significantly enriched in Nordic patients with psoriatic Arthritis Mutilans.
Clinical And Experimental Rheumatology S.A.S, 2021Co-Authors: Nikamo Pernilla, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Padyukov Leonid, Ståhle MonaAbstract:To access publisher's full text version of this article click on the hyperlink belowObjectives: The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic Arthritis Mutilans (PAM), a severe and rare form of psoriatic Arthritis (PsA). Methods: Cohorts of patients with the diagnosis of psoriasis vulgaris with or without Arthritis (n=1217), psoriasis without Arthritis (n=534), psoriatic Arthritis without mutilating disease (n=337) and psoriatic Arthritis Mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes. Results: The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset. Conclusions: HLA-B*27 emerges as an important genotype marker for PAM.UK Research & Innovation (UKRI) Medical Research Council UK (MRC) European Commission Swedish Psoriasis Association Finsen Foundation Karolinska Institutet Nordic Psoriasis Patient Society (NORDPSO
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.Peer reviewe
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study.
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadObjective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged ≥18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.NORDPS
-
Radiographic scoring systems for psoriatic Arthritis are insufficient for psoriatic Arthritis Mutilans: results from the Nordic PAM Study.
'SAGE Publications', 2020Co-Authors: Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Ståhle Mona, Jonmundsson Thorarinn, Gudbjornsson BjornAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadBackground: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis (PsA). Purpose: To describe the radiological features in PAM and explore whether existing scoring systems for radiological damage in psoriatic Arthritis are applicable for PAM. Material and methods: Radiographs were scored according to the modified Sharp-van der Heijde (mSvdH) and the Psoriatic Arthritis Ratingen Score (PARS) systems for PsA. Results: At inclusion, 55 PAM patients (49% women, mean age 58 ± 12 years) had conventional radiographs of both hands and feet. A total of 869 PAM joints were detected and 193 joints with ankylosis. The mean total mSvdH score was 213.7 ± 137.8 (41% of maximum) with a higher score for hands than for feet: 136.6 ± 90.1 vs. 79.1 ± 60.9. However, the total score was relatively higher in the feet than in the hands when compared to the highest possible scoring (47% vs. 38% of max). The mean total PARS score was 126.3 ± 79.6 (35% of max). Scoring for joint destruction was higher than for proliferation (22% vs. 11% of max). Strong correlation was found between mSvdH and PARS (r2 = 0.913). A significant correlation was found between scoring and duration of Arthritis and the Health Assessment Questionnaire. History of smoking, BMI, and gender did not influence the scoring values. Conclusions: The two scoring systems studied may not be ideal to indicate progression of PAM in advanced disease since they reach ceiling effects rather early. Therefore, reporting early signs suggestive of PAM, e.g. signs of pencil-in-cup deformities or osteolysis, is crucial. This would reveal the presence of PAM and might lead to improved treatment in order to minimize joint damage. Keywords: Psoriatic Arthritis; Mutilans; psoriasis; radiology; scoring systems.NORDPS
Lindqvist Ulla - One of the best experts on this subject based on the ideXlab platform.
-
HLA-B*27 is significantly enriched in Nordic patients with psoriatic Arthritis Mutilans.
Clinical And Experimental Rheumatology S.A.S, 2021Co-Authors: Nikamo Pernilla, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Padyukov Leonid, Ståhle MonaAbstract:To access publisher's full text version of this article click on the hyperlink belowObjectives: The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic Arthritis Mutilans (PAM), a severe and rare form of psoriatic Arthritis (PsA). Methods: Cohorts of patients with the diagnosis of psoriasis vulgaris with or without Arthritis (n=1217), psoriasis without Arthritis (n=534), psoriatic Arthritis without mutilating disease (n=337) and psoriatic Arthritis Mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes. Results: The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset. Conclusions: HLA-B*27 emerges as an important genotype marker for PAM.UK Research & Innovation (UKRI) Medical Research Council UK (MRC) European Commission Swedish Psoriasis Association Finsen Foundation Karolinska Institutet Nordic Psoriasis Patient Society (NORDPSO
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.Peer reviewe
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study.
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadObjective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged ≥18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.NORDPS
-
Radiographic scoring systems for psoriatic Arthritis are insufficient for psoriatic Arthritis Mutilans: results from the Nordic PAM Study.
'SAGE Publications', 2020Co-Authors: Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Ståhle Mona, Jonmundsson Thorarinn, Gudbjornsson BjornAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadBackground: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis (PsA). Purpose: To describe the radiological features in PAM and explore whether existing scoring systems for radiological damage in psoriatic Arthritis are applicable for PAM. Material and methods: Radiographs were scored according to the modified Sharp-van der Heijde (mSvdH) and the Psoriatic Arthritis Ratingen Score (PARS) systems for PsA. Results: At inclusion, 55 PAM patients (49% women, mean age 58 ± 12 years) had conventional radiographs of both hands and feet. A total of 869 PAM joints were detected and 193 joints with ankylosis. The mean total mSvdH score was 213.7 ± 137.8 (41% of maximum) with a higher score for hands than for feet: 136.6 ± 90.1 vs. 79.1 ± 60.9. However, the total score was relatively higher in the feet than in the hands when compared to the highest possible scoring (47% vs. 38% of max). The mean total PARS score was 126.3 ± 79.6 (35% of max). Scoring for joint destruction was higher than for proliferation (22% vs. 11% of max). Strong correlation was found between mSvdH and PARS (r2 = 0.913). A significant correlation was found between scoring and duration of Arthritis and the Health Assessment Questionnaire. History of smoking, BMI, and gender did not influence the scoring values. Conclusions: The two scoring systems studied may not be ideal to indicate progression of PAM in advanced disease since they reach ceiling effects rather early. Therefore, reporting early signs suggestive of PAM, e.g. signs of pencil-in-cup deformities or osteolysis, is crucial. This would reveal the presence of PAM and might lead to improved treatment in order to minimize joint damage. Keywords: Psoriatic Arthritis; Mutilans; psoriasis; radiology; scoring systems.NORDPS
Iversen Lars - One of the best experts on this subject based on the ideXlab platform.
-
HLA-B*27 is significantly enriched in Nordic patients with psoriatic Arthritis Mutilans.
Clinical And Experimental Rheumatology S.A.S, 2021Co-Authors: Nikamo Pernilla, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Padyukov Leonid, Ståhle MonaAbstract:To access publisher's full text version of this article click on the hyperlink belowObjectives: The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic Arthritis Mutilans (PAM), a severe and rare form of psoriatic Arthritis (PsA). Methods: Cohorts of patients with the diagnosis of psoriasis vulgaris with or without Arthritis (n=1217), psoriasis without Arthritis (n=534), psoriatic Arthritis without mutilating disease (n=337) and psoriatic Arthritis Mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes. Results: The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset. Conclusions: HLA-B*27 emerges as an important genotype marker for PAM.UK Research & Innovation (UKRI) Medical Research Council UK (MRC) European Commission Swedish Psoriasis Association Finsen Foundation Karolinska Institutet Nordic Psoriasis Patient Society (NORDPSO
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.Peer reviewe
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study.
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadObjective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged ≥18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.NORDPS
-
Radiographic scoring systems for psoriatic Arthritis are insufficient for psoriatic Arthritis Mutilans: results from the Nordic PAM Study.
'SAGE Publications', 2020Co-Authors: Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Ståhle Mona, Jonmundsson Thorarinn, Gudbjornsson BjornAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadBackground: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis (PsA). Purpose: To describe the radiological features in PAM and explore whether existing scoring systems for radiological damage in psoriatic Arthritis are applicable for PAM. Material and methods: Radiographs were scored according to the modified Sharp-van der Heijde (mSvdH) and the Psoriatic Arthritis Ratingen Score (PARS) systems for PsA. Results: At inclusion, 55 PAM patients (49% women, mean age 58 ± 12 years) had conventional radiographs of both hands and feet. A total of 869 PAM joints were detected and 193 joints with ankylosis. The mean total mSvdH score was 213.7 ± 137.8 (41% of maximum) with a higher score for hands than for feet: 136.6 ± 90.1 vs. 79.1 ± 60.9. However, the total score was relatively higher in the feet than in the hands when compared to the highest possible scoring (47% vs. 38% of max). The mean total PARS score was 126.3 ± 79.6 (35% of max). Scoring for joint destruction was higher than for proliferation (22% vs. 11% of max). Strong correlation was found between mSvdH and PARS (r2 = 0.913). A significant correlation was found between scoring and duration of Arthritis and the Health Assessment Questionnaire. History of smoking, BMI, and gender did not influence the scoring values. Conclusions: The two scoring systems studied may not be ideal to indicate progression of PAM in advanced disease since they reach ceiling effects rather early. Therefore, reporting early signs suggestive of PAM, e.g. signs of pencil-in-cup deformities or osteolysis, is crucial. This would reveal the presence of PAM and might lead to improved treatment in order to minimize joint damage. Keywords: Psoriatic Arthritis; Mutilans; psoriasis; radiology; scoring systems.NORDPS
Laasonen Leena - One of the best experts on this subject based on the ideXlab platform.
-
HLA-B*27 is significantly enriched in Nordic patients with psoriatic Arthritis Mutilans.
Clinical And Experimental Rheumatology S.A.S, 2021Co-Authors: Nikamo Pernilla, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Padyukov Leonid, Ståhle MonaAbstract:To access publisher's full text version of this article click on the hyperlink belowObjectives: The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic Arthritis Mutilans (PAM), a severe and rare form of psoriatic Arthritis (PsA). Methods: Cohorts of patients with the diagnosis of psoriasis vulgaris with or without Arthritis (n=1217), psoriasis without Arthritis (n=534), psoriatic Arthritis without mutilating disease (n=337) and psoriatic Arthritis Mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes. Results: The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset. Conclusions: HLA-B*27 emerges as an important genotype marker for PAM.UK Research & Innovation (UKRI) Medical Research Council UK (MRC) European Commission Swedish Psoriasis Association Finsen Foundation Karolinska Institutet Nordic Psoriasis Patient Society (NORDPSO
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:Objective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged >= 18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.Peer reviewe
-
Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study.
'Frontiers Media SA', 2021Co-Authors: Mistegård Josephine, Gudbjornsson Bjorn, Laasonen Leena, Ejstrup Leif, Lindqvist Ulla, Ståhle Mona, Iversen LarsAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadObjective: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged ≥18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.NORDPS
-
Radiographic scoring systems for psoriatic Arthritis are insufficient for psoriatic Arthritis Mutilans: results from the Nordic PAM Study.
'SAGE Publications', 2020Co-Authors: Laasonen Leena, Ejstrup Leif, Iversen Lars, Lindqvist Ulla, Ståhle Mona, Jonmundsson Thorarinn, Gudbjornsson BjornAbstract:To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadBackground: Psoriatic Arthritis Mutilans (PAM) is the most severe phenotype of psoriatic Arthritis (PsA). Purpose: To describe the radiological features in PAM and explore whether existing scoring systems for radiological damage in psoriatic Arthritis are applicable for PAM. Material and methods: Radiographs were scored according to the modified Sharp-van der Heijde (mSvdH) and the Psoriatic Arthritis Ratingen Score (PARS) systems for PsA. Results: At inclusion, 55 PAM patients (49% women, mean age 58 ± 12 years) had conventional radiographs of both hands and feet. A total of 869 PAM joints were detected and 193 joints with ankylosis. The mean total mSvdH score was 213.7 ± 137.8 (41% of maximum) with a higher score for hands than for feet: 136.6 ± 90.1 vs. 79.1 ± 60.9. However, the total score was relatively higher in the feet than in the hands when compared to the highest possible scoring (47% vs. 38% of max). The mean total PARS score was 126.3 ± 79.6 (35% of max). Scoring for joint destruction was higher than for proliferation (22% vs. 11% of max). Strong correlation was found between mSvdH and PARS (r2 = 0.913). A significant correlation was found between scoring and duration of Arthritis and the Health Assessment Questionnaire. History of smoking, BMI, and gender did not influence the scoring values. Conclusions: The two scoring systems studied may not be ideal to indicate progression of PAM in advanced disease since they reach ceiling effects rather early. Therefore, reporting early signs suggestive of PAM, e.g. signs of pencil-in-cup deformities or osteolysis, is crucial. This would reveal the presence of PAM and might lead to improved treatment in order to minimize joint damage. Keywords: Psoriatic Arthritis; Mutilans; psoriasis; radiology; scoring systems.NORDPS
